Table 2. Patient baseline characteristics of the protein array cohort (n=22).
| Characteristic | No. of patients | |
|---|---|---|
| Gender | M/F | 12/10 |
| Age | Median (range) | 63 (44-75) |
| Performance Status | 0/1 | 16/6 |
| Induction chemotherapy regimen | XELOX/FOLFOX | 10 |
| XELIRI/FOLFIRI | 12 | |
| KRAS status | wildtype | 9 |
| mutant | 13 | |
| Response at end of induction treatment | SD/PR | 11/11 |
| Primary tumour location | colon | 10 |
| rectum | 11 | |
| both | 1 | |
| Hypertension | Yes/No | 11/11 |
| Diabetes | Yes/No | 4/18 |
| Cardiovascular disease | Yes/No | 3/19 |
| Thromboembolism | Yes/No | 0/22 |
M= Male, F= Female. Performance status according to ECOG/WHO. KRAS = Kirsten rat sarcoma viral antigen.